Amarantus Bioscience Holdings Inc (AMBS)

[betelgeuse]

There has been a spate of posts moaning how AMBS has put PD and MANF on the bench and all AMBS is doing these days is handwaving at various other indications. Let me be very honest and blunt about this: At the present moment, LymPro is the lifeline for AMBS. LymPro is the engine that will keep AMBS running until it can begin MANF clinical trials in late 2014. Without LymPro, AMBS pps is worth zero dollars. It is LymPro that has kept AMBS at 3-4 cents and it is LymPro that will take AMBS pps to $0.5-1. The amount of work (patents, restructuring, recruitment, partnerships, clearing debts, research milestones) that AMBS has managed to complete in the last 10 months is phenomenal. Learn to give credit where it is due. AMBS has built a pipeline that now resembles like a fortress with multiple levels of defense. If its trials for any one (or more) indications fail, AMBS will be able to still keep moving forward. There is no guarantee that PD MANF trials will be successful. However, LymPro is what will keep AMBS pps from sinking. To be ignorant to the facts is one thing. But to refuse to learn is stupidity. So, before posting aimless nonsense, think. AMBS pps is primed for 5-30X growth. The CLIA partner will be announced in the coming days. MANF-CED partner will be announced soon after Gerald's Europe visit in the first week of September. Stay tuned.